Replies to post #33351 on Cel Sci Corporation (CVM)

[fluteman]

Bio thanks for sharing

[lightrock]

It's a PII-sized study

https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32950

Three-year recurrence rates were assessed for long-term safety analyses. An intent-to-treat analysis revealed that recurrence rates were 12.5% (2/16) in the treatment group and 33.3% (6/18) in the placebo group (P = .239), and in protocol-compliant patients, recurrence rates were 0% (0/11) in the treatment group and 29.4% (5/17) in the placebo group (P = .054).

The ratio is interesting, making a similar scale of suspected difference...